OXFORD BIODYNAMICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.5 GBX | -1.32% |
|
+1.63% | -73.21% |
| Jun. 18 | Oxford BioDynamics revenue up 49% in first half as test sales rise | AN |
| Jun. 18 | Earnings Flash (OBD.L) OXFORD BIODYNAMICS Reports Fiscal H1 Revenue GBP327,000 | MT |
Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST, EpiSwitch PSE, and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patientâs therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
Calendar
2025-01-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -73.21% | 19.62M | |
| +16.59% | 44.44B | |
| +41.02% | 39.84B | |
| -10.62% | 37.68B | |
| +29.92% | 31.46B | |
| -9.23% | 27.02B | |
| +12.34% | 26.29B | |
| +41.53% | 13.8B | |
| +31.49% | 12.46B | |
| -7.40% | 11.26B |
- Stock Market
- Equities
- OBD Stock
- News Oxford BioDynamics Plc
- Earnings Flash (OBD.L) OXFORD BIODYNAMICS Posts Fiscal H1 Loss GBX-2.30
